NWBO Reports $26.8M Q3 Loss, $200K Revenue
Update: 2025-11-15
Description
Northwest Biotherapeutics, a cancer drug developer, reported a significant loss of $26.8 million in Q3, with a loss per share of $18.22. Despite this, the company generated $200,000 in revenue, offering a glimpse into its operational activity. These financial disclosures provide transparency to investors and highlight the financial challenges faced by biotech companies in the research and development phase.
The Daily News Now! — Every city. Every story. AI-powered.
Hosted on Acast. See acast.com/privacy for more information.
Comments
In Channel
Download from Google Play
Download from App Store
United States00:00
00:00
x
